Holen Sie sich die Stockscreener-App
50.21
3.13%
-1.625
Handel nachbörslich:
50.21
Schlusskurs vom Vortag:
$51.84
Offen:
$51.76
24-Stunden-Volumen:
1.07M
Relative Volume:
2.27
Marktkapitalisierung:
$2.42B
Einnahmen:
$2.50M
Nettoeinkommen (Verlust:
$-86.49M
KGV:
-22.27
EPS:
-2.2544
Netto-Cashflow:
-
1W Leistung:
+12.00%
1M Leistung:
+9.13%
6M Leistung:
+115.54%
1J Leistung:
+344.34%
1-Tages-Spanne:
$49.06
$52.86
1-Wochen-Bereich:
$42.88
$52.86
52-Wochen-Spanne:
$6.71
$52.86
Maze Therapeutics Inc Stock (MAZE) Company Profile
Firmenname
Maze Therapeutics Inc
Sektor
Branche
Telefon
(650) 850-5070
Adresse
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
50.21 | 2.49B | 2.50M | -86.49M | 0 | -2.2544 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-04 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-14 | Eingeleitet | Raymond James | Outperform |
| 2025-09-02 | Eingeleitet | BTIG Research | Buy |
| 2025-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-08 | Eingeleitet | Wedbush | Outperform |
Maze Therapeutics Inc Aktie (MAZE) Neueste Nachrichten
Assessing Maze Therapeutics (MAZE) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Maze Therapeutics Executive Sells All Common Stock Holdings - TradingView
Maze Therapeutics stock hits all-time high at 49.28 USD - Investing.com Australia
Maze Therapeutics (NASDAQ:MAZE) Sets New 12-Month HighShould You Buy? - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Shares Up 8.5%Here's Why - MarketBeat
Why Maze Therapeutics Stock Is Suddenly Surging - TipRanks
This Strategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Mizuho Initiates Coverage on Maze Therapeutics (NASDAQ:MAZE) - MarketBeat
Mizuho initiates Maze Therapeutics stock with Outperform rating By Investing.com - Investing.com Canada
Maze Therapeutics’ (MAZE) “Buy” Rating Reaffirmed at BTIG Research - Defense World
Mizuho initiates coverage of Maze Therapeutics (MAZE) with outperform recommendation - MSN
Underappreciated Cardiometabolic Upside: Validating Maze’s SLC6A19 Inhibitor MZE782 and Supporting a Buy on MAZE - TipRanks
Maze Therapeutics' (MAZE) "Buy" Rating Reiterated at BTIG Research - MarketBeat
Buy Rating on Maze Therapeutics: Favorable HORIZON Phase 2 Setup, Validated APOL1 Biology, and Underappreciated Pipeline Upside - TipRanks
MAZE: Lead kidney and metabolic disease programs advance toward pivotal data with strong financial backing - TradingView
Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up Following Analyst Upgrade - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Given New $58.00 Price Target at Guggenheim - MarketBeat
Maze Therapeutics, Inc. (NASDAQ:MAZE) Sees Significant Growth in Short Interest - MarketBeat
Aug Update: What analysts say about Maze Therapeutics Inc stockWeekly Profit Recap & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Pullback Watch: Is Iveda Solutions Inc a good ESG investmentMarket Weekly Review & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Maze Therapeutics, Inc. (MAZE) Stock Analysis: Biotech Innovator with a 10.77% Potential Upside - DirectorsTalk Interviews
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - The Manila Times
Maze Therapeutics Inc CEO set for TD Cowen Health Care event - Traders Union
MAZE Technical Analysis & ETF Price Forecast - Intellectia AI
Buy Rating on Maze Therapeutics Driven by MZE829’s Differentiated APOL1 Mechanism and HORIZON UACR-Reduction Catalyst - TipRanks
Maze Therapeutics, Inc. (MAZE) Stock Analysis: A Biotech With A 9.78% Upside Potential - DirectorsTalk Interviews
Is Maze Therapeutics Inc. forming bullish engulfing patterns2025 Year in Review & Stepwise Entry and Exit Trade Signals - mfd.ru
Latest MAZE ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
Zifo Partners With Maze Therapeutics on Managing Biobank Data - Contract Pharma
Zifo and Maze Therapeutics Partner to Power Precision Medicine - The Malaysian Reserve
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge - AOL.com
Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Earnings Recap: How liquid is Maze Therapeutics Inc stockQuarterly Trade Summary & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge - The Motley Fool
Maze Therapeutics Stock Just Shot Up 24% Pre-Market Today – Here’s What Happened - MSN
MAZE Should I Buy - Intellectia AI
Maze Therapeutics (MAZE) Valuation Check After Strong 1 Year Shareholder Return - Yahoo Finance
Maze Therapeutics Highlights Upcoming MZE829 Kidney Data, Maps Phase 2 Plans for MZE782 at Summit - MarketBeat
Frazier Life Sciences discloses Maze Therapeutics (MAZE) 9% ownership and warrants cap - Stock Titan
Bull Bear: What analysts say about Maze Therapeutics Inc stockGlobal Markets & Weekly High Return Opportunities - baoquankhu1.vn
IPO Launch: Is Maze Therapeutics Inc forming a bullish divergenceJuly 2025 WrapUp & Consistent Return Investment Signals - baoquankhu1.vn
Maze Therapeutics (NASDAQ:MAZE) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Maze Therapeutics, Inc. (MAZE): Investor Outlook on Strong Buy Ratings and 12.50% Upside Potential - DirectorsTalk Interviews
Maze Therapeutics Secures New $200 Million Loan Facility - The Globe and Mail
Amy Bachrodt Sells 5,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - MarketBeat
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells 15,000 Shares of Stock - MarketBeat
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
Maze Therapeutics Signs Loan and Security Agreement With Hercules Capital - TradingView
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Maze Therapeutics stock hits all-time high at 47.47 USD By Investing.com - Investing.com Nigeria
Maze Therapeutics stock hits all-time high at 47.47 USD - Investing.com
Finanzdaten der Maze Therapeutics Inc-Aktie (MAZE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):